Zai Lab (NASDAQ:ZLAB) Stock Crosses Above 50-Day Moving Average – What’s Next?

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)’s share price passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $24.62 and traded as high as $25.99. Zai Lab shares last traded at $25.48, with a volume of 1,894,936 shares trading hands.

Key Stories Impacting Zai Lab

Here are the key news stories impacting Zai Lab this week:

• Positive Sentiment: Zai Lab reported a third-quarter loss of $0.41 per ADS, narrower than analysts’ expected loss of about $0.59. Revenue of $108.21 million also slightly exceeded the $107.90 million estimate, providing a near-term earnings surprise. Earnings Flash
• Positive Sentiment: Investors are also looking toward the pipeline: coverage highlighted the possibility of Zai Lab’s first U.S. drug filing and described 2027 as a pivotal year. Progress toward internally developed medicines could provide future growth catalysts, though outcomes remain uncertain. Zai Lab Q3 2026: Loss Narrows 27%, Pipeline Eyes First US Drug Filing UBS on Q3 performance and 2027
• Neutral Sentiment: UBS said third-quarter performance met expectations, framing the main investment focus as execution on the milestones ahead rather than a major change in near-term results. UBS analysis
• Negative Sentiment: Some earnings coverage said revenue declined and the reported quarterly loss widened, tempering the favorable comparison with analyst estimates. Sustained revenue growth and progress through the pipeline remain important to the outlook. Zai Lab Q3 Loss Widens, Revenue Declines

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Citigroup lifted their target price on shares of Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Zai Lab in a report on Tuesday, October 27th. Wall Street Zen raised shares of Zai Lab from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a report on Tuesday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.25.

Zai Lab Trading Up 12.7%

The firm has a market capitalization of $2.90 billion, a price-to-earnings ratio of -14.23 and a beta of 0.77. The company has a fifty day moving average price of $24.62 and a 200-day moving average price of $21.06.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.18. The firm had revenue of $108.21 million for the quarter, compared to the consensus estimate of $107.90 million. Zai Lab had a negative return on equity of 29.99% and a negative net margin of 44.91%. As a group, sell-side analysts predict that Zai Lab Limited Unsponsored ADR will post -2.37 EPS for the current fiscal year.

Insider Transactions at Zai Lab

In other Zai Lab news, Director William Lis sold 8,506 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $25.00, for a total value of $212,650.00. Following the completion of the sale, the director directly owned 41,931 shares of the company’s stock, valued at $1,048,275. The trade was a 16.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 9,385 shares of company stock valued at $235,145 in the last ninety days. 4.88% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ZLAB. Nan Fung Trinity HK Ltd. increased its position in Zai Lab by 106.9% during the third quarter. Nan Fung Trinity HK Ltd. now owns 293,966 shares of the company’s stock worth $7,743,000 after buying an additional 151,883 shares during the last quarter. Alps Advisors Inc. raised its holdings in Zai Lab by 34.9% during the third quarter. Alps Advisors Inc. now owns 148,993 shares of the company’s stock valued at $3,924,000 after buying an additional 38,562 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Zai Lab during the third quarter valued at about $62,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Zai Lab in the third quarter worth about $211,000. Finally, WealthPlan Investment Management LLC acquired a new stake in shares of Zai Lab in the third quarter worth about $969,000. Institutional investors own 41.65% of the company’s stock.

Zai Lab Company Profile

Zai Lab Ltd. (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.